NPS Pharmaceuticals Hits New 52-Week High at $39.55 (NPSP)
NPS Pharmaceuticals (NASDAQ:NPSP) shares reached a new 52-week high during trading on Monday , Analyst Ratings Network reports. The stock traded as high as $39.55 and last traded at $39.14, with a volume of 1,283,906 shares. The stock had previously closed at $38.57.
A number of analysts have recently weighed in on NPSP shares. Analysts at Zacks reiterated a “neutral” rating on shares of NPS Pharmaceuticals in a research note on Wednesday, February 19th. They now have a $40.00 price target on the stock. Separately, analysts at Needham & Company raised their price target on shares of NPS Pharmaceuticals from $28.00 to $46.00 in a research note on Wednesday, February 19th. They now have a “buy” rating on the stock. Finally, analysts at Jefferies Group downgraded shares of NPS Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, February 19th. They now have a $38.00 price target on the stock. Four analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $40.29.
The stock has a 50-day moving average of $35.93 and a 200-day moving average of $29.57. The company’s market cap is $4.017 billion.
NPS Pharmaceuticals (NASDAQ:NPSP) last announced its earnings results on Thursday, February 27th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.05. The company had revenue of $54.45 million for the quarter, compared to the consensus estimate of $44.22 million. On average, analysts predict that NPS Pharmaceuticals will post $0.32 earnings per share for the current fiscal year.
In other NPS Pharmaceuticals news, Director Georges Gemayel unloaded 6,188 shares of NPS Pharmaceuticals stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $37.70, for a total transaction of $233,287.60. Following the transaction, the director now directly owns 9,000 shares of the company’s stock, valued at approximately $339,300. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
NPS Pharmaceuticals, Inc (NASDAQ:NPSP) is a biopharmaceutical company focused on pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.